Poor air affects you even if you don't smell wildfire smoke: Air pollution explained
The Shasta County Air Quality Management District and Shasta County Health and Human Services Agency advised people — especially those with health issues — to stay indoors when air is smoky.
However, just because you don't smell smoke doesn't mean the air is clean, according to the U.S. Environmental Protection Agency.
Here's where Shasta County's air is smokiest and how air can be polluted even without that smoke smell.
While smoke can fill the air at any time, according to forecasters, Redding, Shasta Lake and Anderson will get more smoke as it settles into the valley at night and early in the mornings, public health said.
Areas most affected by Green Fire smoke are Bella Vista, Palo Cedro, Shingletown, Round Mountain, Big Bend and Burney, according to the county.
Note to readers: If you appreciate the work we do here at the Redding Record Searchlight, please consider subscribing yourself or giving the gift of a subscription to someone you know.
While wildfire smoke is unhealthy, people and animals are also at health risk from what they can't smell.
Fires send a mixture of smoke and tiny particles called PM 2.5 — particulate matter — into the air. When you smell smoke, you're actually smelling just the gases, not the particles, said University of California, San Francisco pulmonologist Dr. John Balmes, an expert on the respiratory and cardiovascular effects of air pollution. Gases and PM 2.5 are side-by-side at the site of a fire, but the particles waft higher into the air at a short distance from the flames.
That's why you can have bad air — air high in PM 2.5 — without smelling smoke or gases.
PM 2.5 contains "microscopic solids or liquid droplets that are so small, they can be inhaled and cause serious health problems,' according to the EPA's PM 2.5 pollution website.
Air quality scientists measure the amount of PM 2.5 in the air. When air quality is ranked "unhealthy," it means there's enough PM 2.5 in the air to cause health problems, according to AirNow.
The particulates "have the ability to get deep into the lung,' Balmes said. 'They cause inflammation, which is the response of the body to injury of any type. When you breathe in these fine particles to your lungs it causes injury. Once there's inflammation in the lungs, it can exacerbate lung (and) heart conditions.'
When air is unhealthy, everyone should reduce the amount of time they spend outdoors if they can, the EPA warns. However, some people are especially vulnerable to the effects of bad air.
When air quality is ranked "unhealthy for vulnerable groups" it means PM 2.5 are at levels that can cause problems for people with medical conditions, especially respiratory issues like asthma and heart or lung disease. Certain age groups — older adults, children and teens — are also vulnerable to problems from bad air, according to the EPA.
When PM 2.5 levels are so high they can hurt anyone, air is ranked "unhealthy", "very unhealthy" or "hazardous" by the EPA. In these cases, everyone should limit prolonged exposure.
The EPA's website at AirNow.gov can tell you how much PM 2.5 is in your air. It also offers health and lifestyle advice based on that result.
Here's what public health branches recommend people do when air is polluted.
Limit outdoor activities.
Remain indoors with the windows and doors closed.
Turn on an air conditioner with a re-circulation setting, like in a vehicle.
If you do go out, choose less strenuous outdoor activities. For example, go for a walk instead of a run.
To learn more about particulate matter go to the California Air Resources Board website at arb.ca.gov/resources/inhalable-particulate-matter-and-health.
Jessica Skropanic is a features reporter for the Record Searchlight/USA Today Network. She covers science, arts, social issues and news stories. Follow her on Twitter @RS_JSkropanic and on Facebook. Join Jessica in the Get Out! Nor Cal recreation Facebook group. To support and sustain this work, please subscribe today. Thank you.
This article originally appeared on Redding Record Searchlight: Don't let poor air quality, wildfire smoke affect you, Californians
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Could cancer drugs be the future of Alzheimer's treatment?
With few treatments available to stop or reverse Alzheimer's disease, scientists have turned to cancer drugs as a potential means of walking back cognitive decline. Alzheimer's cases are rising in the United States and worldwide due to an aging population, but there is no cure for the disease. Attempts to develop new treatments that slow the disease's progress, rather than lessen symptoms, have frequently failed. Only two drugs — the antibody therapies Leqembi and Kisunla — are currently approved by the Food and Drug Administration to slow the progression of early Alzheimer's, and scientists say their benefits are limited. Some pharmaceutical companies have halted or abandoned their Alzheimer's drug development programs because of unsuccessful trials. Others are trying to use existing medications, including popular weight loss drugs, to combat Alzheimer's. With that in mind, researchers at the University of California, San Francisco conducted a broad search for drugs that could be repurposed to treat the condition — in theory, reducing the time in which the drugs could be made available to patients. They scoured a database of more than 1,300 drugs of various classes, including antipsychotics, antibiotics, antifungals and chemotherapy drugs. Then, they looked at how those drugs affected gene expression. Their new study, published Monday in the journal Cell, identified two cancer drugs as the best candidates to lower Alzheimer's risk in patients. When combined, the drugs seemed to slow or reverse Alzheimer's symptoms in mice. One of the drugs is normally used to treat breast cancer, while the other is effective against colon and lung cancer. Alzheimer's disease is associated with significant changes in the way genes are expressed in the brain, leading to the increased production of certain proteins and the decreased production of others. These imbalances may disrupt brain function and contribute to symptoms like memory loss. Fewer than 90 drugs in the researchers' database reversed the expression of signature Alzheimer's-related genes in human brain cells. And five drugs in particular seemed to lower the risk of Alzheimer's in actual patients, based on electronic medical records. The authors ultimately selected two of those drugs, both approved by the FDA to treat cancer, to test in mice. 'We didn't expect cancer drugs to come up' as the most promising, said Marina Sirota, a co-author of the study and interim director of the UCSF Bakar Computational Health Sciences Institute. The authors said the breast cancer drug letrozole seemed to change gene expression in nerve cells. And the colon and lung cancer drug irinotecan seemed to change gene expression in glial cells, which support the nervous system. Alzheimer's can destroy nerve cells and cause glial cells to proliferate, creating inflammation in the brain. In a 2020 study, breast cancer patients who received letrozole were less likely to develop Alzheimer's than patients who did not receive the drug. Colorectal cancer survivors treated with irinotecan also had a decreased Alzheimer's risk, according to a 2021 study. After testing the drugs in mice, the study authors found that the two-drug combo reversed brain degeneration and improved memory in mice that had developed hallmarks of Alzheimer's as they aged. Because results in mice often don't translate to humans, the researchers hope to test the drugs in a clinical trial with Alzheimer's patients. 'Developing a new drug can take hundreds of millions, or even billions, of dollars, on average take more than 10 years. For this repurposed drug, usually it just takes two or three years, and then you can go to the clinical trial and the cost is much, much lower,' said Dr. Yadong Huang, a co-author of the study and professor of neurology at UCSF. 'We still haven't generated or produced any very effective drugs that can really slow dramatically the cognitive decline,' he added. Part of the difficulty in developing drugs for Alzheimer's is the complexity of the disease. Its exact cause is largely unknown. For now, the authors said, it's unclear exactly why the cancer drugs seem to work against Alzheimer's. One theory is that the breast cancer drug blocks the production of estrogen, a hormone that controls the expression of a large number of genes. The colon and lung cancer drug may also block inflammation in the brain by preventing the proliferation of glial cells — though Huang said there are other possibilities. Dr. Melanie McReynolds, an assistant professor of biochemistry at Pennsylvania State University, who was not involved in the study, offered another theory. Her research has suggested that a different type of cancer drug could help treat Alzheimer's by regulating glucose metabolism, the process by which cells make energy. McReynolds said the process is necessary for various brain cells to communicate with each other. 'With aging, with stress, with diseases, that line of communication is disrupted,' she said. McReynolds said the drug combo tested in the new study might reverse metabolic decline — what she called 'the secret for contributing to better outcomes with Alzheimer's.' But assessing how Alzheimer's patients tolerate the combination of cancer drugs will be important. Letrozole can cause hot flashes and irinotecan can cause severe diarrhea. Both drugs can lead to nausea and vomiting. 'These drugs have huge side effects, so you need to always balance and figure out whether those types of side effects would be amenable to somebody with Alzheimer's,' Sirota said. 'It's not that it's a slam dunk.' This article was originally published on Solve the daily Crossword
Forbes
2 hours ago
- Forbes
Draya Michele Is Turning Criticism Into Capital—Starting With Clean Air
With a new investment in wellness tech and a fresh perspective on motherhood, Draya Michele steps confidently into a chapter defined by purpose, power and quiet reinvention. Draya Michele pictured in front of her latest wellness tech investment, Sereniby—a smart air care ... More system designed to support healthier environments for babies and young children. On a sunny afternoon in Santa Monica, California, I settled in for an NAD infusion and Normatec therapy—expecting a routine wellness reset—alongside entrepreneur, designer and now investor Draya Michele. Inside the sunlit sanctuary of Dripology—a sleek, minimalist wellness studio founded by ICU-trained nurse Hamed Afshari to bring medical-grade care into a luxury experience— what began as IV drips, compression boots and a few light laughs quickly unfolded into something far more intimate. The wellness advocate is entering a new era—one rooted in clarity, legacy and deeper intention. Known for her style, and decade-long success with Mint Swim, Draya is now channeling her energy into something far more personal: creating a safer, healthier world for the next generation, starting with her daughter. Watch Full Interview Here For Draya, wellness isn't just a treatment—it's a lifestyle that informs how she lives, parents and does business. And in doing so, she's reminding women—especially Black mothers—that they deserve to breathe deeply, build boldly and define success on their own terms. 'This season of my life feels different,' she tells me, as we settle in for our IV treatments. 'It's personal now. Every decision I make, I think about the impact it has on her.' A Partnership Rooted in Purpose Her newest move is a strategic investment and partnership with Sereniby, a wellness tech company redefining air care for babies and young children. The brand's flagship product—a smart, medical-grade air purifier—goes beyond filtration. It's built to support restful sleep, cleaner breathing environments and peace of mind for modern families. 'This isn't just another brand collab,' Draya clarifies. 'It's ownership. It's alignment. It's me investing in something I wish I had from day one as a mom.' Draya's connection to Sereniby didn't begin in a boardroom—it started in her daughter's nursery. During her pregnancy, she was remodeling her home and found herself surrounded by drywall, paint fumes and dust. 'I remember thinking, 'I can't be breathing this in while I'm growing a baby,'' Draya recalls. 'It made me hyper-aware of how overlooked air quality really is, especially for children.' Sereniby is a modern air purifier designed for nurseries, featuring medical-grade HEPA filtration, ... More whisper-quiet operation, and a gentle nightlight. Its sleek white body and wood-tone base blend seamlessly into any calming, baby-safe space. Sereniby stood out, thanks to a heartfelt note and family photos its founders sent Draya before the product even arrived. 'It wasn't just a product drop. It felt like something bigger,' Draya says. 'The purifier came days later and I was blown away. Not just by the design, but by the thoughtfulness behind it.' With hospital-trusted HEPA and carbon filtration, smart sensors that detect microscopic pollutants, and integrated white noise and light therapy features, Sereniby offered something that matched both her lifestyle and values. As a new mother again, Draya saw the product work firsthand—especially in supporting her daughter's sleep. 'She doesn't sleep easily, so anything that supports rest is gold to me. And if it also protects her health? That's not a luxury. That's essential.' Draya has faced public scrutiny in the past over her parenting style during her early years as a mother—a narrative she's since reclaimed by showing her evolution and deep commitment to growth. The entrepreneur's decision to invest wasn't just about the product—it was about the position. 'It's important to me that my daughter grows up seeing her mother not just as the face of something, but as someone who has a stake in it,' she says. 'I want her to see that we—Black women, Black mothers—belong at the forefront of wellness, parenting and innovation.' Draya Michele enjoying playtime with her daughter, with Sereniby in the background helping keep the ... More air fresh and clean. That positioning is key. As the wellness space grows, Draya's involvement signals a deeper shift: intentional representation at the ownership level. 'I've done collaborations. I've been the ambassador. This time, I wanted equity,' she says. Her investment also challenges the outdated notion that celebrity partnerships are purely transactional. 'This isn't PR. This is my daughter's air. This is our home. I use it every day. That's the difference," Draya expressed. Motherhood looks different this time around. Draya is juggling entrepreneurship, farm life (yes—more on that later), and raising a daughter who demands presence and patience. 'My sons were easy. My daughter? She's attached. She's loud. She's fire,' Draya says, laughing. 'I love it, but I've had to re-learn balance.' That means prioritizing routine, setting boundaries — especially on social media — and redefining what self-care looks like. 'I'm a post-and-go kind of woman now,' she says. 'I've limited who can comment on my posts because peace matters. If I didn't ask for your opinion, I don't need it.' It also means making smarter choices as a consumer and a mom. 'I used to be that person who bought the most expensive baby bottles—imported, hand-blown glass, $80 each,' she shares. 'Now? I'm an Evenflo six-pack for $10 kind of girl. They work just as well, and I don't cry when they break.' Draya Michele carries her daughter in a chest harness during a quiet moment together. Despite the glitz of entrepreneurship and the digital attention that follows her every move, Draya keeps her circle tight—and intentional. 'I'm really blessed to have a group of women around me that don't compete with each other,' she says. 'We all have our own lanes, and we show up for one another in real life.' Her core friend group—rooted in mutual respect, aligned values and zero performative energy—isn't just about vibes. It's protection. 'In this industry, especially as a Black woman, people project so much onto you. It helps to have friends who remind me who I am outside of social media, outside of work, outside of the noise.' And there's been plenty of that noise. Over the years, Draya has navigated harsh public judgment and unsolicited commentary about her personal life—most recently, when she shared an unpaid post about Sereniby during the LA fires, encouraging families to protect their indoor air quality. Santa Monica, California — Friday, June 6: Draya Michele sits down with Forbes contributor Corein ... More Carter for an interactive wellness interview at Dripology, where the two discuss motherhood, legacy, and Draya's newest investment in wellness tech. 'The comments were intense. People were like, 'Draya, people lost their homes—why are you talking about purifiers?' And I get that. But I wasn't speaking to those who experienced loss—I was speaking to the millions of others in LA breathing in that smoke,' she says. 'It came from a pure place. I wasn't paid. I just wanted to help.' Rather than clap back, she chose peace of mind. 'I've learned I don't have to explain everything. But I also won't let people twist my intentions. I believe in what I support.' To guard her peace, Draya has made a simple but profound adjustment: she limits who can comment on her social media posts. 'I post and go. I'm not here to be debated. This is my life, not a group chat,' she says. Though wellness is her latest move, Draya's swimwear brand Mint Swim remains a cultural staple. Known for putting Black and brown women at the forefront of its campaigns since the beginning, Mint Swim continues to champion diversity in a space that once overlooked it. Draya Michele stuns in her signature swimwear line, Mint Swim This past Earth Day, she introduced a limited capsule made from repurposed materials—using her boyfriend's old T-shirts to create new swimwear. 'Fabric waste is a real problem, and fashion contributes to it,' she says. 'I just wanted to do something that felt good and looked good.' With her usual eye for style and practicality, the drop was equal parts thoughtful and fashion-forward. 'It was fun, it was conscious, and it sold out fast,' she notes. 'We'll definitely do more.' In perhaps the most unexpected twist, Draya is now exploring homesteading. On her property, she has 16 chickens, three dogs, a cat and a full vegetable garden. 'I'm learning to grow what I eat. I'm obsessed with the process,' Draya expresses. The farm, like the purifier, represents something larger: autonomy. Peace. Slowness. 'This version of me isn't just about hustle. It's about health. It's about home. I want to show my kids what it looks like to build a full, beautiful life on your own terms.' In her garden, Draya Michele showcases her brand, Mint Swim. She's just as honest when reflecting on her early years as a founder. 'I used to be stubborn. I didn't ask for help. I made expensive mistakes,' she admitted. 'Now? I ask questions. I lean on my peers. You don't have to build alone.' Showing the Woman Behind the Brand In a world that often flattens public figures into brand extensions, Draya is committed to showing her whole self—even if it's unexpected. 'People have assumptions about me,' she admits. 'But the reality is, I'm a mom who recycles, a woman who gardens and someone who genuinely cares about this planet.' One of her quirks? She never litters. 'I'll carry trash in my purse all day before I throw it on the ground,' she says, laughing. 'And if you come to my house, you better write your name on your water bottle. We don't waste around here.' Draya Michele pictured in front of her latest wellness tech investment, Sereniby—a smart air care ... More system designed to support healthier environments for babies and young children. These small rituals—along with her larger moves in sustainability, wellness and conscious parenting—paint a fuller picture of Draya Michele: not just a personality, but a person. 'I'm not trying to be perfect. I'm trying to be real,' Draya adds. 'That's how I humanize myself—by showing up honestly. Whether it's on my farm, in the boardroom or online.' I want to keep showing people what's possible when you operate from intention, not just attention.' And for the little girl watching her every move, Draya's already paving the way. 'This isn't about being perfect. It's about being present. And I hope that everything I do shows my daughter she can build anything—and breathe deeply while doing it.' 'My biggest flex right now isn't a look or a moment,' Draya expresses. 'It's peace. It's alignment. It's knowing that every move I make reflects who I am and what I stand for.' 'I want my daughter to grow up watching me do this with grace, with grit, and with integrity,' Draya says. 'That's legacy. That's impact. That's the kind of woman I'm raising her to be.' And if this chapter is any indication, Draya Michele is just getting started.
Forbes
3 hours ago
- Forbes
A Data-Driven Fix For Orthopedic Practices Losing To Claim Denials
Sally Ragab, Founder & CEO @ Neunetix. Ask any orthopedic group what keeps their CFO up at night, and one answer dominates: denied claims. National surveys show that orthopedics now sees 9% to 11% of all claims rejected. In dollar terms, a 12-surgeon group billing $85 million a year could watch $8 to $10 million slip away before a single appeal is filed. In a recent article, I explored why the problem is worsening across healthcare. Building on this, a multisite analysis conducted by my company suggests that most leakage is preventable—and faster to plug than many administrators think. What We Studied Between April 2024 and March 2025, my company partnered with 12 independent orthopedic practices (across California, Texas, Florida and New York), which collectively submitted 1.26 million claims. We captured every rejection code, payer response time and downstream appeal outcome. Three findings stood out: 1. The overall claim denial rate dropped from 10.4% in the 12 months before the intervention to 6.7% during the six-month intervention period. 2. Preventable denials—such as those caused by missing claim modifiers or lapses in prior authorizations—fell from 64% to 28%. 3. Additionally, the average number of days that claims remained unpaid in accounts receivable decreased from 46 days to 38 days. To achieve this, all practices followed the same three-step process, which I will outline below. There was no need to hire additional full-time staff or change their electronic health record systems. Why Orthopedics Gets Hit Harder 1. High-Ticket Procedures: Hip- and knee-replacement bundles average between $30,000 and $32,000. One denial can wipe out the revenue from hundreds of physical therapy sessions—more than a year of visits for the average patient. 2. Modifier Complexity: Orthopedic procedures often involve complex coding and modifier usage, and many of the most frequently flagged CPT codes for CO-4 and PR-22 edits stem from this specialty—especially when modifiers are missing or missequenced. 3. Authorization Churn: Payers continue to ratchet up pre‑service checks. CMS now requires prior authorization for all hospital outpatient cervical spinal‑fusion procedures with disc removal, and insurance policies, like UnitedHealthcare's 2024 commercial policy, list every major arthroscopy CPT code as "prior authorization required." As a result, authorization‑related denials for outpatient claims jumped 16% in the past three years (registration required). The Three-Step Denial-Prevention Playbook Run a scrape and review electronic claims and payment files (known as ANSI 835/837 files) to identify which billing modifiers are most commonly linked to denials. In our cohort, simple left/right side coding errors (using -RT for right or -LT for left) accounted for 21% of preventable rejections. A one-hour meeting with the coding team to flag and prevent these errors led to a 2.3% point drop in the denial rate within just one month. Add a simple yes/no binary check to the scheduling system so that surgeries can't be booked unless a valid prior authorization ID is included. Clinics that enforced this safeguard reduced their authorization-related denials from 3.7% to 0.9% in just 90 days. A simple predictive model, trained on about 150,000 past claims, was used to flag new claims that were at high risk of denial. Only claims with a risk score of 0.70 or higher were sent to coders for review—everything else moved through automatically. This reduced the average coder workload by 41%, allowing staff to focus more on higher-value appeals. Financial Impact Across the 12 practices, net collections rose $6.4 million in the first six months—roughly $0.75 million per practice—while denial-related write-offs fell 52%. The average site reached cash-flow breakeven on the project in 51 days. Those numbers align with industry surveys, indicating that 65% of orthopedic denials are preventable and that 30% are never reworked at all. Quick Wins Orthopedic Leaders Can Implement Today As a summary, a focused audit of common billing modifier errors—followed by a short retraining session for coding staff—can lead to a 1.5 to 3 percentage-point drop in overall denials. This typically requires no more than two weeks. Next, adding a mandatory prior authorization field to the surgical scheduling system ensures that procedures can't be booked without a valid authorization ID. Clinics that adopted this safeguard saw authorization-related denials fall by 1 to 2.5 percentage points, with rollout taking about 30 days, including staff training. Finally, integrating a simple AI-based risk scoring tool into the claims submission process can further reduce denials by 2 to 4 percentage points. The tool should flag only the highest-risk claims for manual review, cutting coder workload by about 40% and letting teams focus on appeals and other high-value tasks. In my experience, most practices can launch this model within 60 days. Collectively, these steps can push denial rates below the 7.66% improper payment benchmark CMS reports for 2024. Why Act Now • Payer scrutiny is rising. The "State of Claims 2024" report notes a steady climb in authorization-related denials across all specialties, with orthopedics singled out for high-cost implant cases. • Providers feel the pinch. In Experian's 2024 survey, 73% said denials are rising and 67% said payments are taking longer to arrive. • CMS audits are looming. Improper payment probes increasingly target spinal and total-joint bundles; denial records factor into audit risk scores. The Bottom Line Denied claims shouldn't simply be a cost of doing business—they're a solvable data problem. Our field data proves that taking steps like a disciplined five-day audit, a hard scheduling gate and a modest machine-learning layer can slash orthopedic denial rates by one-third and return millions to the bottom line within a quarter. Your implants are cutting-edge—your denial-defense strategy should be too. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
